Renal Biomarker Market Set for Steady Growth, Expected to Reach USD 3,031.8 Million by 2034 at a 7% of CAGR

Future Market Insights’ updated analysis of the renal biomarker ecosystem reveals significant growth opportunities over the next decade. The global renal biomarker market is estimated to be valued at USD 1,541.2 million in 2024, driven by the increasing demand for early and accurate diagnostics for kidney-related diseases.

With growing healthcare awareness and advancements in personalized medicine, the market for renal biomarkers is poised for continued expansion. The market is forecast to reach USD 3,031.8 million by 2034, representing a steady compound annual growth rate (CAGR) of 7% during the forecast period.

Key Factors Hampering the Renal Biomarker Market

• Insufficient validation studies may limit the clinical utility of biomarkers, leading to skepticism among healthcare providers and hindering their integration into routine clinical practice.
• Reimbursement challenges and regulatory requirements pose significant barriers to commercializing and adopting renal biomarker tests.
• The complex regulatory landscape and stringent reimbursement policies can prolong the time to market and raise development costs for biomarker-based diagnostics.

Functional Biomarker Segment to Hold a Significant Share in the Market

Based on biomarker type, the functional biomarker segment stands out, capturing a significant market share of 53.9%.

Functional biomarkers, such as serum creatinine and estimated glomerular filtration rate (eGFR), provide insights into kidney function and are essential for diagnosing and monitoring renal diseases. The widespread adoption reflects their critical role in clinical practice and research.

Enzyme Linked Immunosorbent Assay Segment to Hold a Dominant Share in the Market

Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7 % in 2024. The segment offers high sensitivity and specificity in detecting biomarkers in biological samples, making it a preferred choice for renal biomarker analysis.

The versatility and reliability contribute to its dominant position in the renal biomarker market, catering to the diagnostic needs of healthcare professionals and researchers alike.

Competitive Landscape

A mix of multinational corporations, biotechnology companies, and academic research institutions characterizes the competitive landscape of the renal biomarker market. The companies focus on research and development to innovate new biomarkers, improve diagnostic accuracy, and expand their market reach.

Partnerships, collaborations, and strategic acquisitions are common strategies players employ to strengthen their market position and capitalize on emerging opportunities in the renal biomarker market.

Some of the key developments are

• In December 2022, Journey Biosciences, Inc. unveiled NaviDKD, a pioneering biomarker-based blood test designed to predict long-term kidney complications in individuals with diabetes. The groundbreaking screening technology offered an early warning system for the development of kidney damage in diabetic patients, addressing a critical need for proactive intervention and improved patient outcomes.
• In March 2022, Renalytix plc introduced myIntelX, a state-of-the-art provider access portal aimed at enhancing access to KidneyIntelX prognostic testing. This blood-based biomarker test enabled more precise identification of type 2 diabetes patients at high risk of rapid kidney disease progression.

Key Companies Profiled

• Abbott Laboratories
• BioPorto Diagnostics AS
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Nexelis (Pacific Biomarkers)
• BioMérieux
• Sphingotec GmbH
• Randox Laboratories Ltd
• Siemens Healthineers AG
• Beckman Coulter Inc. (Danaher Corporation)
• Bio-Rad Laboratories Inc.

Access the Full Report

Key Segments

By Biomarker:

• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin
• Up-regulated Proteins
• Neutrophil Gelatinase-Associated Lipocalin
• Kidney Injury Molecule-1
• Interleukin-18
• Others

By Diagnostic Technique:

• Enzyme Linked Immunosorbent Assay (ELISA)
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography-Mass Spectrometry (LS-MS)

By End User:

• Diagnostic Labs
• Outpatient Clinics
• Research Centers
• Hospitals

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• South Asia and Pacific
• East Asia
• The Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube